Tag
India's DCGI has reduced drug approval timelines by over 50%, with marketing authorizations now granted in under 150 days and clinical trial approvals in 120, 135 days. The regulator has also removed mandatory prior approval at the pre-clinical stage, lowering barriers for early drug development. Both changes are in eff
Revolution Medicines shares jumped sharply after clinical trial results for its cancer therapy were characterized as unprecedented. The data point carries outsized weight because RAS-targeted oncology is a historically resistant space where efficacy breakthroughs drive significant pipeline revaluation. Investor attenti
Tag
India's DCGI has reduced drug approval timelines by over 50%, with marketing authorizations now granted in under 150 days and clinical trial approvals in 120, 135 days. The regulator has also removed mandatory prior approval at the pre-clinical stage, lowering barriers for early drug development. Both changes are in eff
2mo ago · 1 min · Policy & Government
Revolution Medicines shares jumped sharply after clinical trial results for its cancer therapy were characterized as unprecedented. The data point carries outsized weight because RAS-targeted oncology is a historically resistant space where efficacy breakthroughs drive significant pipeline revaluation. Investor attenti
2mo ago · 1 min · Markets
— End of feed —